Author Correction: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.
Lu, Hezhe; Liu, Shujing; Zhang, Gao; Wu, Bin; Zhu, Yueyao; Frederick, Dennie T; Hu, Yi; Zhong, Wenqun; Randell, Sergio; Sadek, Norah; Zhang, Wei; Chen, Gang; Cheng, Chaoran; Zeng, Jingwen; Wu, Lawrence W; Zhang, Jie; Liu, Xiaoming; Xu, Wei; Krepler, Clemens; Sproesser, Katrin; Xiao, Min; Miao, Benchun; Liu, Jianglan; Song, Claire D; Liu, Jephrey Y; Karakousis, Giorgos C; Schuchter, Lynn M; Lu, Yiling; Mills, Gordon; Cong, Yusheng; Chernoff, Jonathan; Guo, Jun; Boland, Genevieve M; Sullivan, Ryan J; Wei, Zhi; Field, Jeffrey; Amaravadi, Ravi K; Flaherty, Keith T; Herlyn, Meenhard; Xu, Xiaowei; Guo, Wei.
; 565(7738): E4, 2019 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-30532003
BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma.
Systemic treatments for metastatic cutaneous melanoma.
The impact of melanoma genetics on treatment response and resistance in clinical and experimental studies.
Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma.
Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.
Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both?
Adoptive T-cell transfer therapy and oncogene-targeted therapy for melanoma: the search for synergy.
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.
A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells.